WHEN DO YOU PLAN TO GET
YOUR NEXT CHOLESTEROL TEST?

ESPERION Q3 EARNINGS PRESENTATION

November 2, 2021



FORWARD-LOOKNG STATEMENTS & DISCLOSURES

This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the global clinical development and commercialization plans for bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet, including Esperions timing, designs, plans for announcement of results regarding its CLEAR Outcomes study and other ongoing clinical studies for bempedoic acid tablet and the bempedoic acid / ezetimibe combination fixed dose tablet, timing for the review and approval of expanded indications for their effect on cardiovascular events, Esperion's expectations for the market for medicines to lower LDL-C, including the prospects for success of the commercial launch and market adoption of bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet in the United States and European Union and the Company's overall growth, the development of Esperion's in-licensed pre-clinical oral PCSK9 inhibitor program, and Esperion's financial outlook, including expectations for future revenues from its product sales, partnership collaborations and other sources, expectations for the closing of the Note Exchange and for future transactions to further improve the Company's balance sheet. Any express or implied statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, delays or failures in Esperion's clinical development and the commercialization plans of both Esperion and Daiichi Sankyo group, failure to obtain the approval of bempedoic acid or the bempedoic acid / ezetimibe combination tablet or expanded indications in countries outside of the U.S., or approval of expanded indications, that existing cash resources may be used more quickly than anticipated, that Otsuka and Daiichi Sankyo are able to successfully commercialize its products, the impact of the ongoing COVID-19 pandemic and our corporate workforce reduction and targeted program savings on our business, clinical activities, supply chain, commercial development and launch plans, and the risks detailed in Esperion's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this presentation, other than to the extent required by law.

WITH US TODAY

Business Strategy & Overview

Sheldon Koenig
President and Chief Executive Officer

Q3 2021 Financial Results

Rick Bartram
Chief Financial Officer

Q&A Session



Dr. JoAnne Foody
Chief Medical Officer

Q&A Session

Eric Warren
Head of Sales & Marketing

WHEN DO YOU PLAN TO GET
YOUR NEXT CHOLESTEROL TEST?

BUSINESS OVERVIEW

Sheldon Koenig, President and CEO



Q3 2021 & RECENT HIGHLIGHTS



- Announced **transformative strategic plan and expense structure** to support the long-term growth of NEXLETOL® and NEXLIZET®
- CLEAR Outcomes trial reached **80% MACE Accumulation** in October
- Demonstrated sequential **prescription growth of 10%** from Q2 2021 with over **59,200** cumulative patients
- Hosted **investor webinar** with **world-renowned cardiologist Steven Nissen, M.D.**, from the Cleveland Clinic
- Daiichi Sankyo continues European roll-out of NILEMDO® and NUSTENDI®, with over 28,000 patients now on therapy as of September 30, 2021
- Entered an agreement to exchange $15 million of Esperion convertible notes for common stock ("Note Exchange"), **strengthening the Company's capital position** and providing future financial flexibility
- Appointed Seth H.Z. Fisher to Esperion Board of Directors

WE HAVE A PLAN FOR TRANSFORMATIVE LONG-TERM GROWTH

1. **Optimize organizational structure** and operational processes to enable growth ahead of an inflection post the read-out of the CLEAR Outcomes trial
2. **Reduce overall workforce by 40 percent** and further shift marketing strategy towards a greater proportion of digital and virtual outreach
3. Significantly reduce operational expense in FY 2021 & FY 2022 to generate an estimated **annualized cash savings of at least $80 million**

ENGAGEMENT PROCESS GOING FORWARD

In-Person Medical Communications and Sales Promotion to:

- Targeted Cardiologists, Endocrinologists and PCPs



Leverage Peer-to-Peer Networks to Increase Awareness of Appropriate Place in Treatment Paradigm:

- Specialists to Peer Specialists
- Specialists to Network PCPs

Innovative Digital Promotion to Drive Broad Awareness with:

- Existing Prescribers
- High Potential Specialists and PCPs
- Payers
- Pharmacy
- Integrated Delivery Networks (IDNs)

REPORTED Q3 SALES OF $10.9 MILLION

>59,200 PATIENTS HAVE NOW TAKEN NEXLETOL OR NEXLIZET[(1)]

QUARTERLY FRANCHISE RPE TREND



WEEKLY FRANCHISE RPE TREND SINCE LAUNCH



*Based on Symphony data

RPE = Retail Prescription Equivalence; derived by normalizing the extended units Rx (no. of tablets) to determine the 30-day supply equivalent

(1) As of September 30, 2021

ESPERION

WHEN DO YOU PLAN TO GET
YOUR NEXT CHOLESTEROL TEST?

FINANCIAL UPDATE

Rick Bartram, CFO



RECENTLY ADJUSTED COST STRUCTURE

POSITIONING COMPANY FOR LONG-TERM GROWTH & CURRENT HEALTHCARE ENVIRONMENT

Q3 2021 YTD U.S. Product Revenue	**$28M**
Q3 2021 YTD Ex-U.S. Collaboration Revenue	**$35M**
Q3 2021 Cash, Cash Equivalents, and Restricted Cash[1]	**$154M**
Future Ex-U.S. Collaboration Milestones from Daiichi Sankyo & Otsuka	**>$1.2B**

Key Financial Data	
FY 2021 R&D Guidance	$110 - $115 Million
FY 2021 SG&A Guidance	$195 - $200 Million
FY 2021 Op Ex Guidance[2]	$305 - $315 Million
Q3 2021 Common Shares Outstanding[3]	26.8 Million
FY 2022 Op Ex Guidance[2]	$220-$240 Million

(1) Includes $50 million of restricted cash
(2) Includes $25M of non-cash stock-based compensation expense
(3) Accounts for $50M prepaid forward feature

INVESTMENT HIGHLIGHTS

- Two approved drugs launched in Q2 2020 in the U.S. to lower elevated LDL-cholesterol in specified adults
- CLEAR Cardiovascular Outcomes trial pending 100% MACE accumulation in late 2022 and oral PCSK9i in early-stage development
- Large attractive cholesterol-lowering market with high unmet need
- Experienced management team and Board
- Compelling global partnerships with Daiichi-Sankyo and Otsuka, companies entrenched in the cardiovascular space
- Strong IP protection; anticipated until mid- 2031[1]

(1) Inclusive of anticipated Hatch Waxman and pediatric patent term extensions

THANK YOU

THANK YOU

ESPERION

IMPORTANT SAFETY INFORMATION

ESPERION

NEXLETOL® SAFETY PROFILE

- Contraindications: None
- Warnings and Precautions:
  - Hyperuricemia: NEXLETOL may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout.
  - Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture.
- Avoid concomitant use with simvastatin (>20 mg/day) or pravastatin (>40 mg/day) due to increased risk of adverse events.
- Most common adverse reactions in ≥2% of patients taking NEXLETOL and more frequently than placebo:
  - Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes
- Adverse events reported less frequently but still more often than in placebo included benign prostatic hyperplasia and atrial fibrillation

NEXLIZET® SAFETY PROFILE

- Contraindication: Known hypersensitivity to ezetimibe tablets
- Warnings and Precautions:
  - Hyperuricemia: Bempedoic acid may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout.
  - Tendon Rupture: Bempedoic acid is associated with an increased risk of tendon rupture.
- Avoid concomitant use with simvastatin (>20 mg/day) or pravastatin (>40 mg/day). Monitor cyclosporine concentrations with cyclosporine. If cholelithiasis is suspected in a patient receiving fenofibrate, consider alternative lipid-lowering therapy.
- Most common adverse reactions in >2% of patients taking NEXLIZET and more frequently than placebo:
  - Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, elevated liver enzymes, diarrhea, fatigue, influenza, sinusitis, and arthralgia
- Adverse events reported less frequently but still more often than in placebo included benign prostatic hyperplasia and atrial fibrillation